OR WAIT null SECS
Velabs Therapeutics announced it has deepened its cooperation with Chiome Biosciences to incorporate functional antibody screening as a result of a successful feasibility study.
In an Aug. 27, 2019 press release, Velabs Therapeutics announced it has deepened its cooperation with Chiome Biosciences to incorporate functional antibody screening as a result of a successful feasibility study.
The expanded partnership will involve the discovery of modulatory and functional antibodies for one of Chiome Bioscience’s G protein-coupled receptor (GPCR) target genes using Velabs’ microfluidics-based technology. As per the terms of the agreement, milestone payments will be awarded to Velabs once specific development and regulatory events have been achieved.
“We are delighted about the successful termination of the initial feasibility phase and the current start of a joint development on functional GPCR antibodies,” said Christoph Antz, managing director of Velabs in the press statement.
“Chiome’s decision to continue this project after a successful feasibility study represents an important validation of our technology for the screening and generation of functional antibodies on complex signal proteins like GPCRs,” added Christoph Merten, scientific founder and CSO of Velabs.
“We opted for Velabs’ microfluidic screening technology in order to optimize time and productivity of discovering therapeutic antibodies against GPCRs,” commented Yukoh Nakazaki, head of Antibody Research Laboratories of Chiome Bioscience. “We look forward to obtaining promising hits, which can ultimately give rise to preclinical candidates through this collaboration.”
Source: Velabs Therapeutics